EO3001

News alerts, weekly reports and conference planners

Company:

Edison Oncology

Drug class:

FDX1 inhibitor

‹

›

almost3years

Investigating the therapeutic efficacy of EO3001 in clear cell carcinoma of the ovary (AACR 2023)

We will use the organoids modeling system -using primary endometrial cells harboring ARID1A mutations- to assess the impact of EO3001 on organoid growth and response to stress conditions and evaluate the effect of EO3001 on cancer metastesis by the ex vivo pulmonary metastasis assay (PuMA). Conclusions Exploiting the vulnerability in reliance on OXPHOS in ARID1A-deficient CCC using EO3001 might represent a promising strategy for the treatment of these patients as well as patients harboring other ARID1A-deficient malignancies.

almost 3 years ago

Clinical

PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • ARID1A (AT-rich interaction domain 1A) • SLC7A11 (Solute Carrier Family 7 Member 11)

PIK3CA mutation • ARID1A mutation • AKT1 amplification

EO3001